Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- EXPR -18.3%, GES -13.9%, LE -11.5%, DG -7.7%, NQ -6.7%, ISLE -6.3%, BL -5.3%, KR -4%, BV -3.5%, SNPS -1.9%,CWB -0.7%
M&A news: GNC -3.2% (Bloomberg reported that potential sale talks may have stalled)
Select Brazil related names showing weakness: ABEV -3.8%, ITUB -3.8%, BAK -3.3%, ERJ -2.3%
Select metals/mining stocks trading lower: SBGL -2.8%, AU -2.5%, HMY -2.2%, GOLD -1.4%, AG -0.9%, TCK -0.9%, GG-0.5%
Other news:
Select Brazil related names showing weakness: ABEV -3.8%, ITUB -3.8%, BAK -3.3%, ERJ -2.3%
Select metals/mining stocks trading lower: SBGL -2.8%, AU -2.5%, HMY -2.2%, GOLD -1.4%, AG -0.9%, TCK -0.9%, GG-0.5%
Other news:
- HTBX -58.9% (presents topline HS-410 Phase 2 bladder cancer results; responses did not translate into clinical outcomes, there was no statistically significant difference in the primary endpoint between the vaccine and placebo arms)
- ARDM -54.2% (top-line results from its two Phase 3 clinical trials evaluating the safety and efficacy of Pulmaquin)
- PTN -27.8% (to issue and sell shares of its common stock and warrants to purchase shares of its common stock)
- FCEL -11.1% (announces restructuring, impacting 17% of workforce, cuts production rate in half temporarily; sees Q4 rev below consensus)
- CDZI -6.7% (prices underwritten public offering of 1 mln shares of its common stock at $9.75/share)
- XNCR -5.4% (prices about a 4.6 mln share underwritten public offering of common stock at $24.00/share)
- BEAV -4.2% (Starboard may push for Rockwell to reconsider its pending merger with BEAV)
- PENN -3.2% (attributed to block trade sale)
- MEMP -3.2% (enters into forbearance agreement with noteholders & receives extension of waiver under credit facility )
- GWPH -2.5% (results from two completed Epidiolex Phase 3 trials, one in LGS and one in Dravet syndrome, will be presented at the AES Annual Meeting )
- RXN -2.3% ( commences public offering of 7 mln depositary shares, each of which represents a 1/20th interest in a share of its Series A Mandatory Convertible Preferred Stock)
- KNSL -1.8% (prices secondary offering by selling shareholders of 3,360,000 shares of common stock at $27.50 per shareg)
Analyst comments:
- AA -1.3% (initiated with a Sell at Deutsche Bank)
- WEN -0.6% (downgraded to Neutral from Buy at Guggenheimt)